Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer

Kanamori,

doi:10.4021/jocmr1256w

Cited by 28 publications

(32 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The present study showed that Δbody weight and duration of diabetes were the contributing factors for the maintenance of long-term response, specifically ΔHbA1c (24-3 months) in the completed group. This is why, in contrast to the study of Hamaguchi et al, short-term response alone could not be used to predict the long-term response in the present study compared to the study of Hamaguchi et al Kanamori et al reported similar results to the present study when they found that inadequate compliance with diet and exercise therapy causes weight gain and that increased body weight is associated with the reduced efficacy of sitagliptin therapy (21). Meanwhile, Kubota et al reported that body weight gain between 24 and 52 weeks influences the persistence of the glucose-lowering effect of sitagliptin combined with a sulfonylurea during 1 year of follow-up (22).…”

Section: Discussioncontrasting

confidence: 89%

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

et al. 2015

View full text Add to dashboard Cite

Objective This retrospective study evaluated the long-term efficacy of sitagliptin and the factors contributing to its glucose-lowering effect. Methods Six hundred and sixteen dipeptidyl peptidase-4 inhibitor-naïve outpatients with type 2 diabetes who began sitagliptin treatment between December 1, 2009 and December 31, 2011 were included in this study. The inclusion criteria were that the patient had regularly visited our hospital for a period of ! 700 days from the initiation of sitagliptin treatment and the measurement of hemoglobin A1c (HbA1c) had been performed at 0, 3, 6, 12, 18, and 24 months after the initiation of treatment. From the population of 616 patients, 447 and 169 had received sitagliptin for ! 700 and <700 days, respectively. The primary endpoint was ΔHbA1c at 24 months. The factors associated with the hypoglycemic effect of sitagliptin were also investigated. Results Sitagliptin treatment significantly decreased the level of HbA1c, and the hypoglycemic effect was sustained for at least 2 years. The baseline HbA1c level, duration of diabetes, Δbody weight value, and ΔHbA1c value at 3 months were independently associated with the hypoglycemic effect of sitagliptin. Conclusion Sitagliptin has a long-term hypoglycemic effect in type 2 diabetes patients. A patient's ΔHbA1c at 3 months may be a predictor of their ΔHbA1c at 24 months.

show abstract

Section: Discussioncontrasting

confidence: 89%

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

et al. 2015

View full text Add to dashboard Cite

show abstract

“…Considering these concepts, SGLT2 inhibitors may be a useful addition to the treatment regimen in patients with higher BMI who respond poorly to a DPP‐4 inhibitor. It has also been reported that body weight management is important for maintaining good long‐term glycaemic control with DPP‐4 inhibitors . In the present study, the reductions in HbA1c and body weight were maintained for 52 weeks without attenuation, and 82.24% of patients showed decreases in both HbA1c and body weight at the end of the treatment period.…”

Section: Discussionsupporting

confidence: 60%

“…It has also been reported that body weight management is important for maintaining good longterm glycaemic control with DPP-4 inhibitors. 36,37 In the present study, the reductions in HbA1c and body weight were maintained for 52 weeks without attenuation, and 82.24% of patients showed decreases in both HbA1c and body weight at the end of the treatment period.…”

Section: Discussionmentioning

confidence: 48%

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes

Kadowaki

Inagaki

Kondo

et al. 2017

Diabetes Obesity Metabolism

View full text Add to dashboard Cite

AimTo evaluate the long‐term safety and efficacy of canagliflozin as add‐on therapy in patients with type 2 diabetes mellitus (T2DM) who had inadequate glycaemic control with teneligliptin monotherapy.MethodsThis open‐label 52‐week study was conducted in Japan. Patients received canagliflozin 100 mg added to teneligliptin 20 mg orally once daily for 52 weeks. The safety endpoint was the incidence of adverse events (AEs). The efficacy endpoints included changes in glycated haemoglobin (HbA1c), fasting plasma glucose (FPG) and body weight from baseline to week 52 (with last observation carried forward).ResultsOverall, 153 patients entered the treatment period and 142 completed the study. The overall incidence rates of AEs and drug‐related AEs were 69.9% and 22.9%, respectively. Most AEs and drug‐related AEs were mild or moderate in severity. There were no previously undescribed safety signals. The mean changes in HbA1c, FPG and body weight were −0.99% (95% confidence interval [CI] −1.12 to −0.85), −38.6 mg/dL (95% CI −43.4 to −33.9) and −3.92% (95% CI −4.53 to −3.31), respectively. These effects were maintained for 52 weeks without attenuation. HbA1c and body weight were both decreased in 82.24% of patients at the end of the treatment period. Reductions in postprandial glucose were observed at weeks 24 and 52.ConclusionsNo new safety risks with this combination were identified, and sustained improvements in HbA1c, FPG and body weight were observed. The findings suggest that long‐term co‐administration of canagliflozin with teneligliptin is well tolerated and effective in Japanese patients with T2DM who have inadequate glycaemic control on teneligliptin alone.

show abstract

“…These factors, including dietary habits, exercise, lifestyle, body weight alterations, the insulin secretion capacity and insulin resistance. In addition, the previous report indicated that sitagliptin treatment efficacy was attenuated during the 12-month study period (26). These ideas might have affected the result.…”

Section: Discussionmentioning

confidence: 93%

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes

Kodera

Shikata

Nakamura³

et al. 2017

Intern. Med.

View full text Add to dashboard Cite

Objective Dipeptidyl peptidase-4 (DPP-4) inhibitors are the most frequently prescribed oral hypoglycemic agents in Japan. Although a relationship between the efficacy of DPP-4 inhibitors and the body mass index (BMI) has been reported, this relationship is controversial. We investigated whether the BMI value affects the glucose-lowering efficacy of sitagliptin in obese Japanese patients with type 2 diabetes. Methods One hundred sixty-two outpatients with inadequate glycemic control were divided into four groups based on their baseline BMI values. They were then treated with sitagliptin (a DPP-4 inhibitor) for 3 months and followed-up for 12 months. Results Sitagliptin significantly reduced the hemoglobin A1c level (HbA1c: -0.71±0.55%) after 3 months, and continued to reduce the HbA1c level until 12 months. There was no significant difference in the efficacy of sitagliptin among the four BMI groups. A multiple linear regression analysis indicated that the factors contributing to the change in the HbA1c level were the baseline level of HbA1c and the homeostasis model assessment of β-cell function (HOMA-β). In terms of the relationship between the baseline BMI value and the efficacy of sitagliptin treatment, the number of patients who responded to sitagliptin treatment after 3 months was lowest in the group of patients with the highest BMI values. A multiple logistic regression analysis revealed that the baseline HOMA-β function and HbA1c level and a baseline BMI value of ! 30 kg/m 2 significantly contributed to the response to sitagliptin treatment. Conclusion The results indicated that sitagliptin treatment was effective in controlling glucose metabolism disorder in obese Japanese patients with type 2 diabetes. However, the efficacy of sitagliptin treatment might be attenuated in severely obese patients, such as those with a BMI value of ! 30 kg/m 2 .

show abstract

Factors Associated With Reduced Efficacy of Sitagliptin Therapy: Analysis of 93 Patients With Type 2 Diabetes Treated for 1.5 Years or Longer

Cited by 28 publications

References 23 publications

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

A Reduction of HbA1c after 3 Months Predicts 2-year Responsiveness to Sitagliptin Treatment

Long‐term safety and efficacy of canagliflozin as add‐on therapy to teneligliptin in Japanese patients with type 2 diabetes

The Glucose-lowering Efficacy of Sitagliptin in Obese Japanese Patients with Type 2 Diabetes

Contact Info

Product

Resources

About